These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24341722)

  • 1. Comparison of site-specific PEGylations of the N-terminus of interferon beta-1b: selectivity, efficiency, and in vivo/vitro activity.
    Zhou Z; Zhang J; Sun L; Ma G; Su Z
    Bioconjug Chem; 2014 Jan; 25(1):138-46. PubMed ID: 24341722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.
    Nairn NW; Shanebeck KD; Wang A; Graddis TJ; VanBrunt MP; Thornton KC; Grabstein K
    Bioconjug Chem; 2012 Oct; 23(10):2087-97. PubMed ID: 22988919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific PEGylation at histidine tags.
    Cong Y; Pawlisz E; Bryant P; Balan S; Laurine E; Tommasi R; Singh R; Dubey S; Peciak K; Bird M; Sivasankar A; Swierkosz J; Muroni M; Heidelberger S; Farys M; Khayrzad F; Edwards J; Badescu G; Hodgson I; Heise C; Somavarapu S; Liddell J; Powell K; Zloh M; Choi JW; Godwin A; Brocchini S
    Bioconjug Chem; 2012 Feb; 23(2):248-63. PubMed ID: 22243664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylation of proteins in organic solution: a case study for interferon beta-1b.
    Peng F; Wang Y; Sun L; Liu Y; Hu T; Zhang G; Ma G; Su Z
    Bioconjug Chem; 2012 Sep; 23(9):1812-20. PubMed ID: 22873735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
    Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
    Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins.
    Zhao H; Yang K; Martinez A; Basu A; Chintala R; Liu HC; Janjua A; Wang M; Filpula D
    Bioconjug Chem; 2006; 17(2):341-51. PubMed ID: 16536464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.
    Lee JI; Eisenberg SP; Rosendahl MS; Chlipala EA; Brown JD; Doherty DH; Cox GN
    J Interferon Cytokine Res; 2013 Dec; 33(12):769-77. PubMed ID: 23962003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
    Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
    Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical and enzymatic site specific PEGylation of hGH.
    da Silva Freitas D; Mero A; Pasut G
    Bioconjug Chem; 2013 Mar; 24(3):456-63. PubMed ID: 23432141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.
    Podobnik B; Helk B; Smilović V; Škrajnar Š; Fidler K; Jevševar S; Godwin A; Williams P
    Bioconjug Chem; 2015 Mar; 26(3):452-9. PubMed ID: 25629733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity.
    Lee BK; Kwon JS; Kim HJ; Yamamoto S; Lee EK
    Bioconjug Chem; 2007; 18(6):1728-34. PubMed ID: 17941681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.
    Wu L; Ji S; Shen L; Hu T
    Mol Pharm; 2014 Sep; 11(9):3080-9. PubMed ID: 25115329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action.
    Qiu H; Boudanova E; Park A; Bird JJ; Honey DM; Zarazinski C; Greene B; Kingsbury JS; Boucher S; Pollock J; McPherson JM; Pan CQ
    Bioconjug Chem; 2013 Mar; 24(3):408-18. PubMed ID: 23350694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
    Wu L; Ho SV; Wang W; Gao J; Zhang G; Su Z; Hu T
    Int J Pharm; 2013 Sep; 453(2):533-40. PubMed ID: 23796830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS; Lee KC
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfide-bridging PEGylation during refolding for the more efficient production of modified proteins.
    Ginn C; Choi JW; Brocchini S
    Biotechnol J; 2016 Aug; 11(8):1088-99. PubMed ID: 27213717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.